Tags

Type your tag names separated by a space and hit enter

A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
Eur J Med Chem. 2020 Sep 01; 201:112527.EJ

Abstract

Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed.

Authors+Show Affiliations

School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China. Electronic address: chengyuanliang@gmail.com.School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.Department of Urology Surgery Center, The People's Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, 830002, PR China.Xi'an Taikomed Pharmaceutical Technology Co., Ltd., Xi'an, 710077, PR China.Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, PR China.Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, PR China.Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, PR China. Electronic address: zhaoxush@163.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32563812

Citation

Liang, Chengyuan, et al. "A Promising Antiviral Candidate Drug for the COVID-19 Pandemic: a Mini-review of Remdesivir." European Journal of Medicinal Chemistry, vol. 201, 2020, p. 112527.
Liang C, Tian L, Liu Y, et al. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. Eur J Med Chem. 2020;201:112527.
Liang, C., Tian, L., Liu, Y., Hui, N., Qiao, G., Li, H., Shi, Z., Tang, Y., Zhang, D., Xie, X., & Zhao, X. (2020). A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. European Journal of Medicinal Chemistry, 201, 112527. https://doi.org/10.1016/j.ejmech.2020.112527
Liang C, et al. A Promising Antiviral Candidate Drug for the COVID-19 Pandemic: a Mini-review of Remdesivir. Eur J Med Chem. 2020 Sep 1;201:112527. PubMed PMID: 32563812.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. AU - Liang,Chengyuan, AU - Tian,Lei, AU - Liu,Yuzhi, AU - Hui,Nan, AU - Qiao,Guaiping, AU - Li,Han, AU - Shi,Zhenfeng, AU - Tang,Yonghong, AU - Zhang,Dezhu, AU - Xie,Xiaolin, AU - Zhao,Xu, Y1 - 2020/06/06/ PY - 2020/04/09/received PY - 2020/05/14/revised PY - 2020/06/01/accepted PY - 2020/6/22/pubmed PY - 2020/8/11/medline PY - 2020/6/22/entrez KW - Antiviral KW - COVID-19 KW - Coronavirus KW - RdRP inhibitor KW - Remdesivir (GS-5734) SP - 112527 EP - 112527 JF - European journal of medicinal chemistry JO - Eur J Med Chem VL - 201 N2 - Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed. SN - 1768-3254 UR - https://www.unboundmedicine.com/medline/citation/32563812/A_promising_antiviral_candidate_drug_for_the_COVID_19_pandemic:_A_mini_review_of_remdesivir_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0223-5234(20)30499-2 DB - PRIME DP - Unbound Medicine ER -